Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Moleculin Biotech (MBRX) Operating Expenses (2016 - 2025)

Moleculin Biotech's Operating Expenses history spans 10 years, with the latest figure at $7.5 million for Q4 2025.

  • Quarterly results put Operating Expenses at $7.5 million for Q4 2025, up 13.4% from a year ago — trailing twelve months through Dec 2025 was $25.1 million (down 5.77% YoY), and the annual figure for FY2025 was $25.1 million, down 5.77%.
  • Operating Expenses for Q4 2025 was $7.5 million at Moleculin Biotech, up from $5.9 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $9.1 million in Q3 2022 to a low of $5.2 million in Q4 2021.
  • The 5-year median for Operating Expenses is $6.5 million (2023), against an average of $6.7 million.
  • The sharpest move saw Operating Expenses skyrocketed 48.93% in 2021, then plummeted 34.53% in 2023.
  • Year by year, Operating Expenses stood at $5.2 million in 2021, then soared by 35.41% to $7.0 million in 2022, then increased by 26.55% to $8.9 million in 2023, then dropped by 25.52% to $6.6 million in 2024, then grew by 13.4% to $7.5 million in 2025.
  • According to Business Quant data, Operating Expenses over the past three periods came in at $7.5 million, $5.9 million, and $5.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.